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Abstract 
 
Cancer is now the second-leading cause of mortality and morbidity, behind only heart disease, 
necessitating urgent development of (chemo)therapeutic interventions to stem the growing 
burden of cancer cases and cancer death. Plants represent a credible source of promising drug 
leads in this regard, with a long history of proven use in the indigenous treatment of cancer. This 
study therefore investigated Anacardium occidentale, one of the plants in a Nigerian Traditional 
Medicine formulation commonly used to manage cancerous diseases, for cytotoxic activity. 
Bioassay-guided fractionation, spectroscopy, Alamar blue fluorescence-based viability assay in 
cultured HeLa cells and microscopy were used. Four compounds: zoapatanolide A (1), 
agathisflavone (2), 1, 2-bis (2,6-dimethoxy-4-methoxybenzoyl) ethane (Anacardicin, 3) and 
methyl gallate (4) were isolated, with the most potent being zoapatanolide A with an IC50 value 
of 36.2 ± 9.8 µM in the viability assay. To gain an insight into the likely molecular basis of their 
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observed cytotoxic effects, Autodock Vina binding free energies of each of the isolated 
compounds with seven molecular targets implicated in cancer development (MAPK8, MAPK10, 
MAP3K12, MAPK3, MAPK1, MAPK7 and VEGF), were calculated. Pearson correlation 
coefficients were obtained with experimentally-determined IC50 in the Alamar blue viability 
assay. While these compounds were not as potent as a standard anti-cancer compound, 
doxorubicin, the results provide reasonable evidence that the plant species contains compounds 
with cytotoxic activity. This study provides some evidence of why this plant is used ethno-
botanically in anti-cancer herbal formulations and justifies investigating Nigerian medicinal 
plants highlighted in recent ethno-botanical surveys.  
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1. Introduction 
Cancer is a leading cause of mortality and morbidity, behind only heart disease, with 1 685 210 
new cancer cases and 595 690 cancer deaths expected in the United States alone in 2016
1 
 while 
the current treatments are being sub-optimal
1-2
. In low- and middle-income countries of the 
developing world, the growing burden of new cancer cases and cancer deaths is predicted to 
continue to worsen,
2
 thus requiring renewed global research effort in the development of more 
effective chemotherapeutic agents for cancer management and/or treatment. Plants have been a 
major component of Traditional Medicine (TM), a cultural heritage and system of indigenous 
wisdom adopted for several centuries to manage the health of people in most traditional 
societies. Plants largely represent a credible source of promising drug leads in this regard, as they 
have a long history of proven use
3-11 
in the indigenous treatment of cancer,
12 
e.g., Taxus 
breviflora L. (Taxaceae)
13,14
, Podophylum peltatum L. (Beberidaceae)
15
, Catharanthus roseus G. 
Don (Apocyanaceae)
16
, Raphanus sativus L. (Cruciferae)
17,18
, Combretrum caffrum (Eckl. & 
Zeyh.) Kuntze (Combretaceae),
19
 etc. There is currently a global renaissance of ethno-botanical 
surveys of medicinal plants in traditional societies, most especially in China and India, seeking to 
identify plants having potential anti-inflammatory and anti-cancer activities, amongst other 
activities. In Nigeria, there have been some ethno-botanical surveys of medicinal plants used in 
cancer treatment
20-24
. This has encouraged research into some of these plants in order to discover 
any scientific justification for their ethno-botanical uses. We have been active in this effort, and 
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the study herein reported was initiated as a continuation of our study on Nigerian medicinal 
plants
25
. 
From our interactions with the traditional medical practitioners (TMPs), a herbal formulation 
used for the treatment of cancerous diseases was volunteered (personal communication). The 
formula for the herbal formulation is as follows: ‘Whole plant of Synedrella nodiflora L. Gaertn 
(Asteraceae), the leaves of Alafia barteri Oliv. (Apocyanaceae), the leaves of Anacardium 
occidentale L. (Anacardiaceae) and the aerial parts of Cardiospermum grandiflorum Sw. 
(Sapindaceae) were boiled with water and a tumbler (ca 200 ml) is to be taken three times daily 
for six months.’ This study used a bioactivity-guided approach, which revealed active extracts 
and fractions from which compounds were isolated. We report the identification of four 
compounds (1-4) from A. occidentale, one of the plant constituents of the herbal formulation, 
and the assessment of their potential to kill cancer cells. The binding free energies of each 
compound with target proteins were also calculated and Pearson correlation coefficients were 
plotted using experimentally-obtained IC50 values. 
2. Results and discussion 
 
2.1. Structural elucidation of isolated compounds from A. occidentale 
The crude absolute ethanolic extract of A. occidentale was subjected to chromatographic 
fractionation on silica gel mesh 200-400 and activity was determined using the Alamar Blue cell 
viability assay. The HeLa cell line, a widely-used model of cervical cancer, was used in the 
bioassay-guided isolation of compounds. Four compounds (1-4) were isolated as cytotoxic 
principles from the crude leaf extract. 
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2.1.1. Compound 1 was isolated as a grey-white powder. The proton spectrum showed four 
methyl signals at δH: 1.98 (3H, H-4′), 1.91 (3H, H-14), 1.90 (3H, H-5′) and 1.80 ppm (3H, H-15). 
There were two methylene signals at δH 2.69 (1H, m, H-2a) and 2.20 (1H, m, H-2b), both 
observed to be attached to δc 32.4 (C-2) in the HSQC spectrum.  An aliphatic methine signal was 
observed at δH 2.81 (dd, J = 9.84, 1.3 Hz, H-7), attached to δc 48.3 ppm (C-7) also in the HSQC 
spectrum. Four deshielded methine signals were observed at δH: 4.15 (1H, d, J = 9.4 Hz, H-9), 
4.72 (1H, t, H-3), 4.78 (1H, d, J = 10.9 Hz, H-6) and 5.01 (1H, t, H-8). The remaining signals 
were observed as olefinic proton signals at δH: 5.11 (1H, d, J = 10.6 Hz, H-5), 5.36 (1H, t, H-1), 
5.64 (1H, d, J = 1.3 Hz, H-13a) and 6.31 (1H, d, J = 1.3 Hz, H-13b). Cross peaks were observed 
in the COSY spectrum between the signals at: δH 2.81 and δH 6.31, 5.64 , 5.01; at δH 4.75 and δH 
2.69, 2.17; at δH 4.78 and δH 5.12; at δH 5.35 and δH 2.67, 2.25; at δH 5.01 and δH 4.16, 2.81. The 
carbon 13 and DEPT spectra revealed 20 signals in all at δC: 169.2 (Cq, C-12), 166.9 (Cq, C-1′), 
141.0 (CH, C-2′), 140.7 (Cq, C-12), 135.5 (2Cq, C-4, 10),126.9 (=CH2, C-13), 126.7 (CH, C-3′), 
124.7 (CH, C-5), 123.3 (CH, C-1), 80.6 (CH, C-9), 75.5 (CH, C-6), 72.9 (CH,C-8), 67.7 (CH, C-
3), 48.5 (CH, C-7), 32.4 (CH2, C-2 ), 20.4 (CH3, C-5′), 17.3  (CH3, C-15), 16.0 (CH3, C-4′) and 
11.8 (CH3, C-14). In the HMBC spectrum, long range correlation was observed between the 
proton signal at δH 1.80 and the carbon signals at δc: 67.7, 123.3 and 141.4. Also, long range 
correlations were observed between the following set of signals: δH 1.90 and δc 80.6, 124.7, 
135.5; δH 1.91 and δc 126.7, 140.7, 166.9; δH 1.98 and δc 140.7, 126.9; δH 5.01 and δc 80.8; δH 
5.11 and δc 75.6; δH 5.64 and δc 169.2 and finally between δH 6.30 and δc 48.5, 169.2. The NMR 
spectrum suggested a germacrane framework (δH 1.89, s, Me-14 and δ 1.79 d, J = 1.5 Hz, Me-
15) with oxygenated functions at C-3, C-6, C-8, and C-9, while an α-methylene-γ-lactone [δ 
169.2 (C-12), 135.5 (C-11), and 126.0 (C-13); δH 5.67 and 6.30 (H-13)] was also evident. The 
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remaining signals were from the esterification with angelic acid, with the total carbon atom being 
20. The molecular formula for 1 was indicated from the LTQ Orbitrap XL FTMS as C40H52O12 
from mass spectrum signal at m/z of 747.3351 [2M + Na]
+
 (calculated mass 747.3351). The 
1
H 
NMR data were in good agreement with that obtained for the heliangolide, Zoapatanolide A, 
isolated from Montana tomentosa
26, 27, 28
 and we herein present its carbon-13 data for the first 
time. Therefore, 1 was identified as Zoapatanolide A. To the best of our knowledge, this is the 
first report of an α-methylene-γ-lactone from Anacardiaceae. 
 
2.1.2. Compound 2 was isolated as a brown amorphous powder. ESI-MS spectrum gave a peak 
at m/z 561 (M + Na)
+
. The NMR data of 2 (Section 2.2) when compared with literature data
27,28 
allowed the assignment of 2 as agathisflavone.  
 
2.1.3. Compound 3 was isolated as a greyish white powder. The molecular formula of 
C22H26O8 was determined based on the HR ESI-Q-TOF MS at m/z 441.1529 [M + Na]
+
 
calculated for C22H26O8 Na (441.1525). In the HSQC spectrum, the proton signal at δH: 3.82 
correlated with two carbon signals at δc: 52.3 and 56.3, an indication of two overlapping proton 
signals at δH: 3.82. These signals were observed to possess long-range correlation with the 
signals at δc 146.6 and 168.9 in the HMBC spectrum.  Also, the signal at δH 7.03 was observed 
to correlate with the carbon signals at δc: 109.8, 121.2, 146.6 and 168.9. However, the MS peak 
at m/z 441 (M+Na)
+
 is for a molecular formula C22H26O8, and a m/z unit twice the mass expected 
for a Methyl-3,5-dimethoxyl-4- methyl benzoate indicates the existence of a dimer. Thus, 
compound 3 is determined to be 1,2-bis (2,6-dimethoxy-4-methoxybenzoyl) ethane 
(Anacardicin). An analogue of the compound, 2, 2-dicarboxy-4,4′,5,5′-tetramethoxy dibenzyl 
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dimethyl ester, was synthesized by Battersby and Binks,
29
 from Pavine through Hofmann’s 
degradation reaction.  
 
2.1.4 Compound 4 was isolated as a brown powder. The ESI-MS spectrum showed a peak at 
m/z 183 (M-1)
+
. On comparison of the NMR data with literature data
30
, Compound 4 was 
determined to be methyl gallate. 
 
2.2. Spectroscopic data for compounds 1, 2, 3 and 4 
2.2.1. Zoapatanolide A (1) was isolated as ash-coloured amorphous powder. m.p. 195-196
0
C. 
1
H NMR  (400 MHz, CD3OD): δH 1.80 (3H, H-10″), 1.90 (3H, H-9″),1.91 (3H, H-7″), 1.98 (3H, 
H-8″), 2.20 (1H, m, H-4b′), 2.69 (1H, m, H-4a′), 2.81 (dd, J = 9.84, 1.3 Hz, H-4″), 4.15 (1H, d, J 
= 9.4Hz, H-7′), 4.72 (1H, t, H-3′), 4.78 (1H, d, J = 10.9 Hz, H-3), 5.01 (1H, t, H-8), 5.11 (1H, d, 
J = 10.64 Hz, H-1′), 5.36 (1H, t, H-5′), 5.64 (1H, d, J = 1.3 Hz, H-3″) and 6.31 (1H, d, J = 1.3 
Hz, H-5″). 13C NMR (100 MHz, CD3OD). δC :169.2 (Cq, C-12), 166.9 (Cq, C-1′), 141.0 (CH, C-
2′), 140.7 (Cq, C-12), 135.5 (2Cq, C-4, 10), 126.9 (=CH2, C-13), 126.7 (CH, C-3′), 124.7 (CH, 
C-5), 123.3 (CH, C-1), 80.6 (CH, C-9), 75.5 (CH, C-6), 72.9 (CH,C-8), 67.7 (CH, C-3), 48.5 
(CH, C-7), 32.4 (CH2, C-2 ), 20.4 (CH3, C-5′), 17.3  (CH3, C-15), 16.0 (CH3, C-4′) and 11.8 (CH3, 
C-14).  LTQ Orbitrap XL FTMS  m/z 747.3351 [2M + Na]
+
, i.e.,  two moles of C20H26O6 Na 
(cal. 747.3351). 
 
2.2.2. Agathisflavone (2) was isolated as brown amorphous powder. 
1
H NMR (400 MHz, 
CD3OD) δH: 7.95 (2H, d, J = 8.9 Hz, H-3′,5′), 7.57 (2H, d, J = 8.8 Hz, H-3″′, 5″′), 6.99 (2H, d, J 
= 8.8 Hz, H-2′,6′), 6.72 (1H, s, H-6), 6.71 (1H, s, H-3), 6.63 (1H, s, H-3″),  6.57 (2H, d, J = 8.8 
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Hz, H-2″′, 6″′), 6.39 (1H, s, H-8″). 13C NMR (100 MHz, CD3OD). δC: 183.3 (Cq, C-4/C-4′′), 
164.2 (Cq, C-2,9/2″,9″), 162.8 (Cq, C-5/5″), 162.6 (Cq,C-7/7″), 162.2 (Cq, 4′/4″′), 129.3 (C-
3′,5′/3″′,5″′), 123.6 (Cq, C-10/10″), 123.4 (Cq, C-8/1′/6″/1″′),  117.1 (CH, C-2′,6′/2″′,6″′), 103.4 
(CH, C-3/3″) and 94.6 (CH, C-6/8″). LC ESI-MS m/z 561 (M + Na)+ , 537 (M-1).+ 
 
2.2.3. Anacardicin [1,2-bis(2,6-dimethoxy-4-methoxycarbonyl)ethane] (3): 
1
H NMR (400 
MHz, CD3OD): δH 3.82 (6H, s, OCH3-8, 8′), 3.82 (6H, s, OCH3-9, 9′) and 7.04 (4H, s, H-3/5, H-
3′/5′). 13C NMR (100 MHz): δc: 168.9 (Cq, C-7,7′), 146.6 (Cq, C-2, 2′, 6, 6′), 121.3 (Cq, C-1/1′, 
4/ 4′), 109.8 (CH, C-3/3′, 5/ 5′), 56.3 (OCH3, C-9/9′), 52.3 (OCH3, C-8/8′) and 30.6 (CH2, C-
10/10′). HR ESI-Q-TOF MS m/z 441.1529 [M + Na]+ calculated for C22H26O8 Na (cal. 
441.1525). 
 
2.2.4. Methyl gallate (4): 
1
H NMR  (400 MHz, CD3OD): δH  3.72 (3H, s, OCH3), 6.94 (2H, s, 
H-2/6). 
13
C NMR (100 MHz): δc: 168.9 (Cq, C-7), 146.6 (Cq, C-3,5), 139.8 (Cq, C-4), 121.1 
(Cq, C-1), 110.2 (CH, C-2/6), 52.3 (OCH3, C-8). LC ESI MS m/z 183 [M - 1].
+
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Figure 1: Structures of compounds 1-4 and their IC50 values  
  
2.3. Effects of extracts, fractions and isolated compounds on cell viability  
Screening in HeLa cells was conducted sequentially, starting from acetone-soluble and acetone-
insoluble extracts. The acetone-soluble extract showed activity while the acetone-precipitated 
extract did not show any activity. The acetone-soluble extract at 50 µg/ml and 100 µg/ml 
reduced HeLa cell viability to 90% and 9%, respectively, and was fractionated further on silica. 
The most-potent fraction from the extract reduced viability to 35%. This was subjected to further 
purifications, producing fractions, the most-potent of which achieved a reduction to 5% of cell 
viability at 100 µg/ml. Four compounds that showed activity were eventually isolated. The 
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effects of each of the four AO compounds on the viability of HeLa cells after 48 h incubation of 
the cultures with increasing concentrations of the compound up to 1.6 mM were then fully 
examined. The anti-cancer agent doxorubicin was used as a positive control and reference 
compound. Doxorubicin at 1, 2.5 and 5 µM yielded cell viability values of 106.5%, 50.8% and 
40.0%, respectively (n=2) (IC50 circa 2.3 µM). All the test compounds elicited concentration-
dependent reductions in HeLa cell viability but with varying potencies as revealed by their IC50 
values, with the order of decreasing potencies being zoapatanolide A (1) (IC50 = 36.2 ± 9.8 µM)> 
anacardicin (3) (IC50 = 46.5 ± 4.1 µM)> agathisflavone (2) (IC50 = 84.7 ± 11.5 µM)> methyl 
gallate (4) (IC50 = 267.2 ± 29.4 µM) (Figure 2). For each compound, the degrees of reduction in 
cell viability correlated well with the extent of morphological damage seen in the corresponding 
photomicrographs. As compound concentrations were increased, there was greater loss of cells 
and more rounding up of the remaining cells. Representative photomicrographs for the most 
potent compound identified as zoapatanolide A (1), an α-methylene-γ- sesquiterpene lactone, are 
shown (Figure 3), compared to and contrasted with those of agathisflavone (2), which is more 
than twice less potent. The cytotoxic potentials of α-methylene-γ- sesquiterpene lactone had been 
well reported in literature.
31-33 
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Figure 2. Concentration-dependent compound-induced reductions in HeLa cell viability (for 
Compounds 1-3). Cultures were incubated with a range of concentrations of the compounds for 
48 h and viability was assessed using Alamar blue. Corresponding concentration-response curve 
fits for the calculation of IC50 values are also shown (IC50 values are as indicated on the curves). 
The IC50 value for Compound 4 is 267.2 ± 29.4 µM (n=3-4). The anti-cancer agent doxorubicin 
was used as a positive control and reference standard, with an estimated IC50 of approximately 
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2.3 µM. The rank order of increasing potencies of the compounds is  Zoapatanolide A (1) > 
Anacardicin (3) > Agathisflavone (2) > Methyl gallate (4). ***P<0.001, compared to the 
negative control (DMSO only). Experiments were carried out at least three times (n=3 for 1 and 
3 and n=4 for 2). 
 
 
 
Figure 3. Effects of isolated compounds on the morphology of HeLa cells. Concentration-
dependent damaging effects of representative compounds (abbreviated Cpd) zoapatanolide A 
(Cpd 1) and agathisflavone (Cpd 2) are compared and contrasted. Zoapatanolide A (Cpd 1) is 
more than twice as potent as agathisflavone (Cpd 2). For example, as shown, Cpd 1 at 50 µM 
caused significant damage to the cells whereas Cpd 2 at the same concentration elicited no 
significant damage. Damage was manifested by loss of cells and rounding up of remaining cells, 
compared to control cultures which were confluent and remained intact. Images were acquired, 
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following 48 h treatments, on a Nikon Eclipse TS100 inverted microscope (x10 magnification) 
fitted with a camera. Scale bar = 20 µm.  
 
2.4. Computational studies on isolated compounds 
All four compounds demonstrated strong binding to the seven protein targets, with the exemption 
of an unfavourable energetics computed for 2 against MAPK7. In most cases, the binding of 2 to 
the cancer drug targets suggests stronger interaction with the binding site residues than the 
interaction of each of the other three compounds. To identify which of the protein-inhibitor 
systems best reproduced the experimentally-observed inhibition, a correlation of the obtained 
binding energetics against IC50 values was performed. Three MAP kinases, MAPK1 (correlation 
coefficient of 0.71), MAPK8 (correlation coefficient of 0.67) and MAPK3 (correlation 
coefficient of 0.60) produced significant correlation patterns (Table 1). Interestingly, inhibition of 
the three MAP kinases have been implicated in anticancer activity of other natural products34,35. 
In other words, while the experimentally-observed inhibitory effects of the compounds may not 
be fully explained by their binding to the computationally-examined targets in the present work, 
the obtained analysis strongly suggests somewhat significant roles for the three kinases in the 
obtained inhibition. It is not inconceivable to expect the inhibitors to bind and interact with a 
much wider network of molecular targets relevant to cancer, in which case the inhibition 
observed in vitro represents a gross averaging of the cumulative binding and inhibitory effects at 
several molecular targets. As such, employing multiple targets in analysis, as has been performed 
in this work, provides a more robust description of the molecular events resulting in cytotoxic 
potencies. Analysis of the specific interactions for MAPK1 reveals a plurality of binding site 
interactions for the different compounds (Figure 4, Figure 5 and Figure 6). Doxorubicin, for 
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instance, relies on extensive network of hydrophobic contacts involving amino acid residues like 
Ile29, Val37, Gln103, Met106, Thr108, Ser151, Leu154 and Cys164 (Figure 6). Compound 2 
additionally recruits multiple directional hydrogen bonds with Met106, Glu69 and Asp165, 
which translates into a stronger binding site interaction as revealed in the resulting energetics 
(Figure 5).  Compound 1 in additional to multiple hydrophobic contacts also formed hydrogen 
bond with the amide nitrogen of Ala33, employing one of the hydroxyl groups present in the 
molecule (Figure 5). Compound 3 formed no hydrogen bonds, a phenomenon that partially 
resulted from the absence of proton donors in the structure (Figure 4). The strength of its 
hydrophobic interactions can be highlighted by noting that a more favourable energetic was 
obtained (-6.4 kcal), compared with compound 4 (Figure 4) which formed three hydrogen bonds 
(-5.4 kcal) (Table 1). By relying on both hydrogen bond and extensive hydrophobic contacts, 
therefore, compound 1 was able to interact with critical amino acid residues in the binding site of 
MAPK1, which we believe contributes, at least in part, to its profile of inhibition observed in the 
cell viability assay. 
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Fig. 4: Top: Surface representation of bound zoapatanolide A (1) (left) 
and agathisflavone (2) (right) within the MAPK1 binding site. Bottom: binding site 
interactions, with thin dashed lines indicating hydrophobic contacts 
and the thicker green lines showing hydrogen bonding with 
zoapatanolide A (1) (left) and agathisflavone (2) (right). 
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Fig. 5: Top: Surface representation of bound anacardicin (3) (left) 
and methyl gallate (4) (right) within the MAPK1 binding site. Bottom: binding 
site interactions, with thin dashed lines indicating hydrophobic 
contacts and the thicker green lines showing hydrogen bonding with 
compounds anacardicin (3) (left) and methyl gallate (4) (right). 
 
17 
 
 
 
Fig. 6: Top: Surface representation of bound doxorubicin within the MAPK1 
binding site. Bottom: binding site interactions, with thin dashed lines 
indicating hydrophobic contacts and the thicker green lines showing 
hydrogen bonding. 
 
 
 
Compound 
 
IC50  
(μM) 
Binding free energy (kcal/mol) 
MAPK8  MAPK10  MAP3K12 MAPK3  MAPK1 VEGF MAPK7  
1 36.2 -6.4 -7.0 -6.6 -8.2 -7.1 -6.8 -4.6 
18 
 
2 84.7 -7.9 -9.9 -8.6 -11.3 -8.3 -10.8
  
+3.6 
3 46.5 -6.4 -7.4 -6.3 -7.8 -6.4 -6.9 -6.0 
4 267.2  -5.5  -5.8 -6.1 -6.0 -5.4 -5.6 -5.9 
Doxorubicin 2.3 -8.4 -7.5 -7.8 -9.5 -7.9 -9.2 -6.3 
P.e.i. 1.0000 0.67 0.45 0.41 0.60 0.71 0.50 -0.03 
Table 1: Autodock Vina binding free energies and Pearson correlation coefficients with 
experimentally-obtained IC50 values. The underlined correlation coefficients indicate significant 
correlation patterns.  
 
2.5. Nigerian medicinal plants as a source of lead compounds 
Information about curative effects of Nigerian medicinal plants and recipes used by traditional 
medical practitioners (TMPs) to treat various diseases is difficult to obtain due to many factors, 
including perceived lack of trust between the TMPs and the scientists. Many of the custodians of 
the indigenous knowledge are old and a lot of information is being lost due to lack of 
documentation. The plant investigated in this study was chosen based on volunteered 
information from a TMP. Ashidi et al
22
 concluded that the TMPs do have good understanding of 
the cancerous disease conditions and of the treatment outcomes. This study of one of the 
constituent plants in the volunteered recipe indicates that the plant has potential anti-tumour 
activity. Four compounds were isolated from the plant. One of them, the biflavonoid 
agathisflavone, had been reported to have antiproliferative activity against Jurkat cells, with an 
IC50 value of 4.45 µM,
36 
with apoptosis as its main mechanism of action. The much higher IC50 
value (lower potency) obtained in our study could be attributed to differences in cell types used, 
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as the study that reported the antiproliferative activity of agathisflavone on Jurkat cells found that 
its strong effect was cell-specific, as it showed modest or marginal cytotoxicity in the other cell 
lines (HL60, Raji, Hep-2) tested. The study also assessed cell proliferation using tritiated 
thymidine (radioligand) incorporation assay, whereas we assessed cell viability through a 
fluorescence-based method. In our study, the most potent of the compounds, zoapatanolide A (α-
methylene-γ-sesquiterpene lactone), has been found to act as a Micheal acceptor with the thiol 
group of cysteines in proteins, thereby modifying the protein covalently
37,38,39
. The other 
compounds are anacardicin and gallic acid. While many salicylic acid derivatives with cytotoxic 
activities have been isolated from the juice of A. occidentale,
40
 this work is the first to report the 
isolation of zoapatanolide A, an α-methylene-γ-sesquiterpene lactone, and anacardicin from the 
leaf extract of A. occidentalis and explore the possible molecular basis for their observed 
cytotoxic activities.  
3. Conclusion 
A. occidentale contains compounds with some cytotoxic activity, which might justify its 
inclusion in Nigerian herbal recipes for the management of cancer. Thus, Nigerian medicinal 
plants represent a veritable source of lead compounds for cancer drug discovery and 
development.  
 
4.  Material and Methods 
4.1. General 
1
H and 
13
C NMR spectra (for both 1D and 2 D experiments) were obtained on the Bruker AV400 
(IconNMR) Spectrometer at 400 and 100 MHz, respectively, while the LCMS analyses were 
carried out on an Agilent LC-MS comprising a 1100 series LC/MSD Trap SL at the Analytical 
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Center of the University of Bradford, United Kingdom. The HRMS data for Compound 1 
(zoapatanolide A) were acquired at the Engineering and Physical Sciences Research Council 
(EPSRC) National Mass Spectrometry Facility, College of Medicine, Groove Building, Swansea 
University, Swansea, UK, and at Petermaritzburg Mass Service, Department of Chemistry, 
University of Kwazulu-Natal, South Africa. Adsorption chromatography (open column) was 
performed with Kieselgel 60 (ASTM 230–400 mesh, Merck). Size exclusion column 
chromatography was achieved on Sephadex LH-20 (Pharmacia) pre-swollen in specified solvent 
before loading onto the column. All Thin Layer Chromatography (TLC) analyses were 
performed at ambient temperature using analytical silica gel 60 GF254 pre-coated aluminum 
backed plates (Merck, 0.25 mm thick). The resulting spots on TLC plates were visualized under 
UV light (254 nm) and detected by the use of 1% vanillin/H2SO4. 
 
4.2. Collection of the plants vegetative parts 
The leaves of Anacardium occidentale (IFE 17446) were collected on Road 9, Obafemi 
Awolowo University Staff quarters in April 2014. The plant’s vegetative parts were identified by 
Mr. A.A. Ogunlowo of the Department of Pharmacognosy and deposited in the IFE Herbarium. 
The leaves were air-dried at room temperature and powdered.  
 
4.3. Fractionation of the crude extract and isolation of compounds from A. occidentale 
The powdered leaves (1.6 kg) were extracted with absolute ethanol (5 x 2.5 L) for two days and 
the crude extract was concentrated in-vacuo to yield 380 g. The crude extract was dissolved in 
500 ml of water and the solution was subjected to acetone precipitation by adding 100% acetone 
(2.5 L) until precipitate started coming out and it was left for six hours. The supernatant (acetone 
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soluble fraction) was concentrated to dryness in vacuo to give 80 g. The precipitate yielded 246 
g. Only the acetone-soluble fraction inhibited viability of Hela cells and was therefore 
fractionated on silica gel (mesh 230-400, column 30 x 5 cm) using solvent mixtures of increasing 
polarities from 100% CHCl3 through 100% EtOAc to 100 % MeOH. About 20 ml of the eluate 
was collected into each test tube. The contents of the test tubes were analyzed on TLC using the 
following solvent mixtures as mobile phases: 100% CHCl3, CHCl3: EtOAc (1:1), 100% EtOAc, 
EtOAC:MeOH (9:1), EtOAc:MeOH:H2O:AcOH (10:2:1:0.2) and BuOH:MeOH:H2O (6.5:3.5:1). 
Each chromatogram was viewed under the UV lamp at both 254 and 366 nm and was sprayed 
with 10% sulphuric acid in methanol. Test tubes with similar TLC profiles were bulked together 
to give fractions (AO is an abbreviation for A. occidentale) AO1 (11.0 g), AO2 (1.5 g), AO 
3(21.1 g), AO 4 (12.9g), AO 5 (14.9 g) and AO 6 (11.2 g). All the fractions were subjected to the 
Alamar blue-based cell viability assay as already described in this paper. Only fraction AO 2 
elicited toxicity in Hela cells. This was fractionated further on silica gel mesh 230-400 using an 
open column (20 x 2 cm) with gradient elution starting with 100% CHCl3 through 100% EtOAc 
to 40% MeOH. Eluates of about 10 mls were collected in small sample bottles and were 
analyzed on TLC with 100% EtOAc as mobile phase. Test tubes with similar TLC profiles were 
bulked to give AO 2A (0.094 g), AO 2B (0.028 g), AO 2C (0.034), AO 2D (0.469 g), AO 2E 
(0.189 g) and AO 2F (0.745 g). Only AO 2A (eluted with 10% EtOAc in CHCl3), AO 2B (eluted 
with 30% EtOAc in CHCl3) and AO 2F (eluted with 10-30% MeOH in EtOAc) showed toxicity 
against Hela cells. Fraction AO 2F with relatively good weight was therefore repeatedly 
subjected to isocratic elution using 5% MeOH in EtAOc to give agathisflavone (2) (0.242 g, 
0.015% w/w), zoapatanolide A (1) (0.120 g, 0.0075 % w/w), anacardicin (3) (0.043 g, 0.0027 % 
w/w) and methyl gallate (4) (0.196 g, 0.012 % w/w) as pure compounds. 
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4.4. Cell viability assay and microscopy 
HeLa cells were plated into black, flat-bottomed 96-well plates at a density of 1 x 10
5
 cells/ml 
(100 µl/well)
41
 using as the growth medium Minimum Essential Medium (MEM) supplemented 
with 10% Foetal Bovine Serum (FBS), 1% non-essential amino acid (NEAA), glutamine (2 mM) 
and 1% antibiotic-antimycotic solution. The cells were incubated for 24 h at 37
o
C in a 
humidified atmosphere of 5% CO2 before they were exposed to a range of concentrations of the 
test compounds for 48 h. Alamar Blue (AB) was used to quantify cell viability as previously 
described (3 h of incubation with AB, cooling plates to room temperature and reading plates 
(fluorescence: excitation at 530 nm (544 nm used), emission at 590 nm) on FlexStation 3 
(Molecular Devices))
41.
 Values for compound-treated wells were compared with those of control 
wells that were treated with DMSO only. Control values were then set at 100% and values for 
the compound-treated wells were normalized to the control values. Changes to the morphology 
of the cells induced by test compounds were monitored on a Nikon Eclipse TS 100 inverted 
microscope fitted with a camera. 
4.5.  Data analysis 
Values are shown as Mean ± SEM (standard error of the mean). Statistical analysis was done 
using GraphPad (Version 7.01, GraphPad Software, Inc., CA, USA). One-way analysis of 
variance (ANOVA) was used to compare the differences between means, followed by Dunnett’s 
multiple comparisons test (comparison of each treatment mean to the control mean). A p-value 
of <0.05 was considered statistically significant. To calculate IC50 values, viability data were fit 
to the non-linear regression equation log (inhibitor) versus response - variable slope (four 
parameters).   
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4.6. Computational modeling  
There are several molecular targets implicated in cancer development with which a compound 
demonstrating anticancer property can bind to. In this study, rather than employ a single 
molecular target, we have employed seven different proteins. Six of these (including MAPK8, 
MAPK10, MAP3K12, MAPK3, MAPK1 and MAPK7) are mitogen-activated protein kinases 
involved in growth and cell proliferation, differentiation, apoptosis and migration42; while the 
seventh is the vascular endothelial growth factor (VEGF) that is important in angiogenesis and 
metastasis by extension43. High resolution crystal structures of inhibitor-protein complexes 
corresponding to MAPK8, MAPK10, MAP3K12, MAPK3, MAPK1 and MAPK7 and VEGF 
were downloaded from the RCSB database and with accession codes and resolution 4QTB. PDB 
: 1.4 A, 4ZZN.PDB ; 1.33 A, 4ZSG.PDB ; 1.79 A, 4QTD.PDB ; 1.50 A, 4W4W.PDB ; 1.90 A, 
5CEP.PDB ; 1.99 A, and 3WZD.PDB ; 1.57 A, respectively. Coordinates of the inhibitors were 
removed from the complexes after which docking grids were generated using AutoDock Tool44,45 
focusing on the binding site residues as identified in the crystallographic structures. Following 
this, AutoDock Vina46 was employed in docking each of the energy-minimized 3D structures 
(treated as flexible) of zoapatanolide A (1), agathisflavone (2), anacardicin (3), methyl gallate (4) 
and doxorubicin against each of the seven protein receptors (treated as rigid). An exhaustiveness 
of 4 was employed. The computed binding free energies and structures for the top conformations 
were saved for post-docking analysis. To gain an insight into the likely molecular basis of the 
observed cytotoxic effects of the investigated compounds, Pearson correlation coefficient was 
calculated using the formula: 
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𝑃e.i =
(
1
𝑁
∑ (𝑒𝑖 − ?̄?)
𝑁
i=1 (𝑖𝑖 − 𝑖̄))
(√(
1
𝑁
∑ (𝑒𝑖 − 𝑒)2
𝑁
i=1 ) × √(
1
𝑁
∑ (𝑖𝑖 − 𝑖)2
𝑁
i=1 ))
 
 where the numerator captures the sample variance. The two denominators represent the 
standard deviations for the computed binding energy (e) and the experimentally-observed IC50 
value (i), while their mean values are denoted with ?̄? and 𝑖̄, respectively. 
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